Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEAM: Bardoxolone Methyl in Type 2 Diabetes and CKD
NCT00811889Phase 2Completed
- Sponsor
- Biogen
- Start
- Apr 2009
- Primary completion
- May 2010
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bardoxolone methyl in diabetic nephropathy (DN) (4 arms), sponsored by Biogen. Primary endpoints: Change in eGFR from baseline at 24 weeks and Safety and tolerability of bardoxolone methyl at 52 weeks. Started Apr 2009; status: completed.
02
Drugs
bardoxolone methyl
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT00811889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00811889.